Christie L Bell

Christie L Bell is a prominent inventor based in Boston, MA (US), known for her significant contributions to the field of gene transfer technologies. With a total of five patents to her name, she has made remarkable advancements in the understanding and application of adeno-associated virus (AAV) vectors.

Latest Patents

One of her latest patents focuses on compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer. This innovative method involves modifying a clade F cell surface receptor that contains a glycan with a terminal sialic acid residue and a penultimate β-galactose residue. The technique allows for the retargeting of the vector by temporarily functionally ablating AAV9 binding in a subset of cells, redirecting the vector to another subset. Additionally, it enhances cellular uptake efficiency by treating cells with neuraminidase to expose cell surface β-galactose. The patent also includes compositions containing the AAV9 vector and neuraminidase, methods for purifying AAV9 using β-galactose linked to solid support, and mutant vectors modified to alter their targeting specificity.

Career Highlights

Christie L Bell is affiliated with the University of Pennsylvania, where she continues to push the boundaries of research in gene therapy. Her work has garnered attention for its potential applications in treating various genetic disorders.

Collaborations

She collaborates with notable colleagues, including James M Wilson and Luc H Vandenberghe, who share her passion for advancing gene transfer technologies.

Conclusion

Christie L Bell's innovative work in gene transfer technologies exemplifies her commitment to improving medical treatments through scientific research. Her contributions are paving the way for future advancements in the field.

This text is generated by artificial intelligence and may not be accurate.